Challenges in familial chylomicronemia syndrome diagnosis and management across latin american countries: an expert panel discussion

Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels due to impaired clearance of chylomicrons from plasma. This paper is the result of a panel discussion with Latin American specialists who raised the main issues on diagnosis and man...

Descripción completa

Detalles Bibliográficos
Autores: Lorenzatti, Alberto J., Nogueira, Juan Patricio, Cafferata, Alberto M., Aimone, Daniel, Lourenco, Charles Marques, Izar, Maria Cristina De Oliveira, de Lima, Josivan Gomes, Lottenberg Pita, Ana Maria, Alonso, Rodrigo, Garay, Karla
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2021
País:Colombia
Institución:Universidad El Bosque
Repositorio:Repositorio U. El Bosque
Idioma:inglés
OAI Identifier:oai:repositorio.unbosque.edu.co:20.500.12495/7066
Acceso en línea:http://hdl.handle.net/20.500.12495/7066
https://doi.org/10.1016/j.jacl.2021.10.004
Access Level:acceso abierto
Palabra clave:FCS
Familial chylomicronemia syndrome
Hypertriglyceridemia
Clinical phenotype
Descripción
Sumario:Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by extremely high triglyceride levels due to impaired clearance of chylomicrons from plasma. This paper is the result of a panel discussion with Latin American specialists who raised the main issues on diagnosis and management of FCS in their countries. Overall FCS is diagnosed late on the course of the disease, is characterized by heterogeneity on the occurrence of pancreatitis, and remains a long time in care of different specialists until reaching a lipidologist. Pancreatitis and secondary diabetes are frequently seen, often due to late diagnosis and inadequate care. Molecular diagnosis is unusual; however, loss of function variants on the lipoprotein lipase gene are apparently the most frequent etiology. A founder effect of the glycosylphosphatidylinositol anchored high density lipoprotein binding protein 1 gene has been described in the northeast of Brazil. Low awareness of the disease amongst health professionals contributes to inadequate care and an inadequate patient journey.